The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques—implications for recombinant vaccine design
- 7 July 2010
- journal article
- research article
- Published by Springer Nature in Immunogenetics
- Vol. 62 (9) , 593-600
- https://doi.org/10.1007/s00251-010-0461-0
Abstract
The yellow fever vaccine 17D (YF17D) is one of the most effective vaccines. Its wide use and favorable safety profile make it a prime candidate for recombinant vaccines. It is believed that neutralizing antibodies account for a large measure of the protection afforded to YF17D-vaccinated individuals, however cytotoxic T lymphocyte (CTL) responses have been described in the setting of YF17D vaccination. YF17D is an ssRNA flavivirus that is translated as a full-length polyprotein, several domains of which pass into the lumen of the endoplasmic reticulum (ER). The processing and presentation machinery for MHC class I-restricted CTL responses favor cytoplasmic peptides that are transported into the ER by the transporter associated with antigen presentation proteins. In order to inform recombinant vaccine design, we sought to determine if YF17D-induced CTL responses preferentially targeted viral domains that remain within the cytoplasm. We performed whole YF17D proteome mapping of CTL responses in six Indian rhesus macaques vaccinated with YF17D using overlapping YF17D peptides. We found that the ER luminal E protein was the most immunogenic viral protein followed closely by the cytoplasmic NS3 and NS5 proteins. These results suggest that antigen processing and presentation in this model system is not preferentially affected by the subcellular location of the viral proteins that are the source of CTL epitopes. The data also suggest potential immunogenic regions of YF17D that could serve as the focus of recombinant T cell vaccine development.Keywords
This publication has 24 references indexed in Scilit:
- Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoeliiVaccine, 2010
- Recombinant Yellow Fever Vaccine Virus 17D Expressing Simian Immunodeficiency Virus SIVmac239 Gag Induces SIV-Specific CD8 + T-Cell Responses in Rhesus MacaquesJournal of Virology, 2010
- Compartmentalized MHC class I antigen processing enhances immunosurveillance by circumventing the law of mass actionProceedings of the National Academy of Sciences, 2010
- The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell ResponseThe Journal of Immunology, 2009
- Case of Yellow Fever Vaccine–Associated Viscerotropic Disease with Prolonged Viremia, Robust Adaptive Immune Responses, and Polymorphisms in CCR5 and RANTES GenesThe Journal of Infectious Diseases, 2008
- The Antiviral Efficacy of Simian Immunodeficiency Virus-Specific CD8 + T Cells Is Unrelated to Epitope Specificity and Is Abrogated by Viral EscapeJournal of Virology, 2007
- Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genesVirology Journal, 2007
- Attenuation of Recombinant Yellow Fever 17D Viruses Expressing Foreign Protein Epitopes at the SurfaceJournal of Virology, 2005
- Yellow fever 17D as a vaccine vector for microbial CTL epitopesThe Journal of Experimental Medicine, 2005
- Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virusJournal of Molecular Biology, 2002